Study to Assess the Efficacy and Safety of Favipiravir-HU
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess the safety and efficacy of Favipiravir HU when administered
to SARS-Cov- 2 patients in order to offer a safe and effective treatment to SARS-Cov-2
infection during the pandemic. The study is not for registration purposes and is not part of
a series of studies for registration of Favipiravir HU.